Print
Email
Print Edition StoriesMonday, January 18, 2010
Catabasis Pharma pulls in $2M
By Mass High Tech staff
MHT's Julie Donnelly: Pharmaceuticals find drug development partners in colleges
Robotic surgery gains traction
Funding drugs for rare diseases
Cambridge-based biotech startup Catabasis Pharmaceuticals Inc. has raised about $2 million in an amendment to a filing with the U.S. Securities and Exchange Commission.
The company develops drugs to treat inflammatory diseases, according to its website. The developments are aimed at improving the conditions of inflammatory bowel disease, diabetes, psoriasis, rheumatoid arthritis and multiple sclerosis. Catabasis claims it has already demonstrated in vitro and in vivo proof of concept for its CAT1000 compounds.
The $2 million funds stem from an intended $3 million debt round.
Christopher Thomajan, chief financial officer of Catabasis, was not immediately available to discuss the filing.
The company previously filed an amendment to an SEC filing in May, noting that it had raised $1.075 million of a $2 million debt round.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
